<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg"/></p>
<p>两家公司将共同监督抗体候选药物的早期开发。来源：SmartPhotoLab / Shutterstock.com。</p>
<p>SciNeuro Pharmaceuticals 宣布与诺华制药达成全球许可和合作协议，以开发 SciNeuro 新发现的去新型淀粉样β抗体项目，旨在治疗阿尔茨海默病。</p>
<p>该协议将利用 SciNeuro 的专有血脑屏障运输技术，旨在与当前正在开发或市场上的淀粉样β药物形成潜在差异化。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM：礼来公司的 Remternetug</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM：SanBio 有限公司的 SB-623</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>两家公司将共同监督抗体候选药物的早期开发。在初始阶段之后，诺华将承担全球范围内所有后续产品开发和商业化的责任。</p>
<p>根据协议条款，SciNeuro 将获得 1.65 亿美元的预付款。该公司还可能获得研究资金，以及高达 15 亿美元的潜在开发、监管和商业里程碑。还将提供分级版税。</p>
<p>交易的完成预计在 2026 年上半年，需遵循 1976 年哈特 - 斯科特 - 罗迪诺反垄断改进法案的等待期结束或豁免，并满足惯例的成交条件。</p>
<p>SciNeuro 创始人兼首席执行官 Min Li 表示：“抗淀粉样蛋白项目是 SciNeuro 针对神经退行性疾病的关键战略研发优先事项之一。我们很高兴能与诺华合作继续开发这一项目，考虑到其在神经退行性疾病下一代疗法方面的卓越能力和承诺。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>“这次合作实现了最佳的协同效应，将我们在疾病生物学和早期开发方面的专业知识与诺华在临床开发和商业化方面的全球领导地位相结合。”</p>
<p>诺华生物医学研究神经科学全球负责人 Robert Baloh 表示：“迫切需要新的和差异化的治疗方法，以帮助缓解阿尔茨海默病等毁灭性神经疾病的痛苦。</p>
<p>“我们很高兴能与 SciNeuro 合作，该组织拥有专有技术，旨在安全有效地靶向淀粉样β，并与我们对这一疾病领域的紧迫感和承诺相一致。”</p>
<p>2025 年 10 月，诺华与美国 Avidity Biosciences 签署了一项协议，以 120 亿美元的现金收购其所有未偿还股份，按完全稀释基础计算。</p>

诺华制药

<p>SciNeuro Pharmaceuticals 与诺华制药达成了一项全球许可协议，旨在开发用于阿尔茨海默病的淀粉样β抗体。此次合作将重点关注早期开发，诺华将在后期阶段和商业化方面接手。SciNeuro 将获得 1.65 亿美元的预付款、潜在的研究资金以及高达 15 亿美元的里程碑付款。该交易预计将在 2026 年上半年完成，待监管机构批准。两家公司旨在利用各自的专业知识，满足对新阿尔茨海默病疗法的迫切需求</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg"/></p>
<p>Both companies will jointly oversee early-stage development of the antibody candidates. Credit: SmartPhotoLab / Shutterstock.com.</p>
<div class="lb-trans"><p>两家公司将共同监督抗体候选药物的早期开发。来源：SmartPhotoLab / Shutterstock.com。</p>
</div><p>SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s newly identified de novo amyloid beta antibody programme aimed at treating Alzheimer’s disease.</p>
<div class="lb-trans"><p>SciNeuro Pharmaceuticals 宣布与诺华制药达成全球许可和合作协议，以开发 SciNeuro 新发现的去新型淀粉样β抗体项目，旨在治疗阿尔茨海默病。</p>
</div><p>The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market.</p>
<div class="lb-trans"><p>该协议将利用 SciNeuro 的专有血脑屏障运输技术，旨在与当前正在开发或市场上的淀粉样β药物形成潜在差异化。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Eli Lilly and Co's Remternetug</h4>
<div class="lb-trans"><h4>NPVM：礼来公司的 Remternetug</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: SanBio Co Ltd's SB-623</h4>
<div class="lb-trans"><h4>NPVM：SanBio 有限公司的 SB-623</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Both companies will jointly oversee early-stage development of the antibody candidates. Following the initial stages, Novartis will assume responsibility for all further product development and commercialisation worldwide.</p>
<div class="lb-trans"><p>两家公司将共同监督抗体候选药物的早期开发。在初始阶段之后，诺华将承担全球范围内所有后续产品开发和商业化的责任。</p>
</div><p>Under the agreed terms, SciNeuro will receive an upfront payment of $165m. The company may also receive research funding, along with up to $1.5bn in potential development, regulatory and commercial milestones. Tiered royalties will also be available.</p>
<div class="lb-trans"><p>根据协议条款，SciNeuro 将获得 1.65 亿美元的预付款。该公司还可能获得研究资金，以及高达 15 亿美元的潜在开发、监管和商业里程碑。还将提供分级版税。</p>
</div><p>Completion of the transaction is anticipated in the first half of 2026, subject to the end or waiver of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period and fulfilment of customary closing conditions.</p>
<div class="lb-trans"><p>交易的完成预计在 2026 年上半年，需遵循 1976 年哈特 - 斯科特 - 罗迪诺反垄断改进法案的等待期结束或豁免，并满足惯例的成交条件。</p>
</div><p>SciNeuro founder and CEO Min Li said: “The anti-amyloid programme represents one of SciNeuro’s key strategic R&amp;D priorities to target neurodegenerative disease. We are thrilled to collaborate with Novartis to continue its development, given its preeminent capabilities and commitment to next-generation therapies for neurodegenerative diseases.</p>
<div class="lb-trans"><p>SciNeuro 创始人兼首席执行官 Min Li 表示：“抗淀粉样蛋白项目是 SciNeuro 针对神经退行性疾病的关键战略研发优先事项之一。我们很高兴能与诺华合作继续开发这一项目，考虑到其在神经退行性疾病下一代疗法方面的卓越能力和承诺。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>“This collaboration delivers an optimal synergy, combining our expertise in disease biology and early development with Novartis’ global leadership in clinical development and commercialisation.”</p>
<div class="lb-trans"><p>“这次合作实现了最佳的协同效应，将我们在疾病生物学和早期开发方面的专业知识与诺华在临床开发和商业化方面的全球领导地位相结合。”</p>
</div><p>Novartis biomedical research neuroscience global head Robert Baloh said: “There is a pressing need for new and differentiated therapeutics to help alleviate suffering in devastating neurological diseases such as Alzheimer’s disease.</p>
<div class="lb-trans"><p>诺华生物医学研究神经科学全球负责人 Robert Baloh 表示：“迫切需要新的和差异化的治疗方法，以帮助缓解阿尔茨海默病等毁灭性神经疾病的痛苦。</p>
</div><p>“We are happy to be collaborating with SciNeuro, an organisation which has proprietary technology aiming to safely and effectively target amyloid beta and which shares our sense of urgency and commitment to this disease area.”</p>
<div class="lb-trans"><p>“我们很高兴能与 SciNeuro 合作，该组织拥有专有技术，旨在安全有效地靶向淀粉样β，并与我们对这一疾病领域的紧迫感和承诺相一致。”</p>
</div><p>In October 2025, Novartis signed an agreement to acquire all outstanding shares of US-based Avidity Biosciences for $12bn in cash on a fully diluted basis.</p>
<div class="lb-trans"><p>2025 年 10 月，诺华与美国 Avidity Biosciences 签署了一项协议，以 120 亿美元的现金收购其所有未偿还股份，按完全稀释基础计算。</p>
</div>

SciNeuro 与诺华制药签署全球许可协议，开发阿尔茨海默症抗体